ABIVAX (EPA:ABVX) | Finanzwire

Basculer en Français

11008	Companies
241194	Keywords
169754	Articles
129837	Press releases

Home
Companies
ABIVAX

PRESS RELEASE

published on 10/06/2025 at 10:00, 11 months 10 days ago

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
Abivax announces late-breaking presentation at UEG Meeting on ABTECT Induction Trial results in patients with and without prior inadequate response to advanced therapies. Obefazimod shows clinically meaningful improvements and favorable safety profile

Abivax Obefazimod Ulcerative Colitis Clinical Trial Late-breaking Presentation
BRIEF

published on 10/05/2025 at 17:05, 11 months 11 days ago

Abivax Presents Promising 8-Week ABTECT Trial Results

Abivax Obefazimod Ulcerative Colitis Clinical Trials Safety Data
PRESS RELEASE

published on 10/05/2025 at 17:00, 11 months 11 days ago

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Abivax announces positive results from Phase 3 ABTECT 8-Week Induction Trials on obefazimod for ulcerative colitis treatment with no new safety concerns identified, to present further abstract on October 6

Abivax Obefazimod Ulcerative Colitis Phase 3 Trial Safety Data
BRIEF

published on 10/03/2025 at 11:59, 11 months 13 days ago

JP Morgan Chase & Co. crosses the 5% threshold at ABIVAX

Voting Rights Actions Abivax Threshold Crossing JP Morgan
BRIEF

published on 09/29/2025 at 22:10, 11 months 17 days ago

Abivax Presents New Findings on Obefazimod at UEG 2025

Abivax Obefazimod Ulcerative Colitis Phase 3 Trials UEG Meeting
PRESS RELEASE

published on 09/29/2025 at 22:05, 11 months 17 days ago

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
Abivax announces acceptance of additional late-breaking abstract from the ABTECT Phase 3 induction trials to be presented at 2025 United European Gastroenterology (UEG) Meeting

Abivax Ulcerative Colitis Gastroenterology Late-breaking Abstract ABTECT Phase 3
BRIEF

published on 09/23/2025 at 22:10, 11 months 23 days ago

Abivax: Presentation of promising data on obefazimod at the 2025 UEG congress

Abivax Obefazimod Ulcerative Colitis Phase 3 UEG Congress
PRESS RELEASE

published on 09/23/2025 at 22:05, 11 months 23 days ago

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
Abivax announces presentation of late-breaking abstract for Obefazimod at 2025 United European Gastroenterology Meeting, showcasing potential as a new therapy for ulcerative colitis

Abivax Obefazimod Ulcerative Colitis Late-breaking Abstract UEG Meeting
BRIEF

published on 09/16/2025 at 18:05, 1 year ago

ABIVAX: Distribution of Share Capital and Voting Rights

Euronext Paris Share Capital Voting Rights AMF Abivax
BRIEF

published on 09/16/2025 at 10:04, 1 year ago

JP Morgan Chase exceeds 5% threshold in ABIVAX

Capital Actions Abivax Threshold Crossing JP Morgan Chase

Accesswire

Published on 09/16/2026 at 23:45, 9 hours 47 minutes ago

Galway Metals Settles Claim by Former Employee with Cash and Share Payments
Published on 09/16/2026 at 21:30, 12 hours 2 minutes ago

Torq Completes $1.7 Million Private Placement
Published on 09/16/2026 at 16:55, 16 hours 37 minutes ago

CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 15:00, 18 hours 32 minutes ago

2026 Canada's Top 40 Under 40(R) Honourees Announced
Published on 09/16/2026 at 14:00, 19 hours 32 minutes ago

Ameriwest Awaits Bornite Core Assay Results and Provides Q3 2026 Corporate Update

View all ACCESSWIRE

EQS Group

Published on 09/17/2026 at 09:28, 3 minutes ago

KNDS THL20 TURRETS SELECTED FOR INDIA’S NEW LIGHT COMBAT HELICOPTER PROGRAM
Published on 09/17/2026 at 09:00, 32 minutes ago

Encavis completes EUR 282 million non-recourse project financing for 351 MW solar PV portfolio in Italy
Published on 09/17/2026 at 09:00, 32 minutes ago

Removal - UDI STEERS Notes Series 2007-1
Published on 09/17/2026 at 09:00, 32 minutes ago

Grünenthal announces pricing of €850 million of bonds
Published on 09/17/2026 at 09:00, 32 minutes ago

Official List Notice

Les Echos

Published on 09/16/2026 at 20:46, 12 hours 45 minutes ago

LNA SANTE : 2026 First Half Results
Published on 09/16/2026 at 17:45, 15 hours 47 minutes ago

5th edition of “On the way up” show
Published on 09/16/2026 at 17:45, 15 hours 47 minutes ago

Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 2 hours ago

bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 15 hours ago

Report on the Combined General Meeting of the 10th of September 2026

View all LES ECHOS COMFI WIRE